Eli Lilly Shares Soar on Foundayo Demand
Shares of Eli Lilly surged 15% in Monday's trading session, adding approximately $90 billion in market capitalization after the company disclosed that pre-orders for its new oral weight loss medication Foundayo have shattered internal projections. The stock closed at an all-time high, cementing Eli Lilly's position as the most valuable pharmaceutical company in the world.
The dramatic move came after the company released preliminary first-quarter data showing that Foundayo prescriptions in its first six weeks of availability have exceeded the launch trajectories of every previous GLP-1 medication, including the company's own blockbuster Mounjaro and Zepbound.
The Numbers Behind the Surge
According to Eli Lilly's disclosure, key metrics from Foundayo's launch include:
- Pre-orders: Over 2.1 million prescriptions have been written since the drug's March launch, exceeding the company's initial projection of 800,000 for the first quarter.
- Revenue projection: Wall Street analysts have revised their 2026 Foundayo revenue estimates upward to $8 to $12 billion, from initial projections of $4 to $6 billion.
- Market share: Foundayo has already captured an estimated 12% of new GLP-1 prescriptions, remarkable given its recent entry into a crowded market.
- Patient demographics: Approximately 40% of Foundayo prescriptions are going to patients who have never previously taken a GLP-1 medication, indicating the oral formulation is expanding the total addressable market.
Why Foundayo Is Different
The market enthusiasm for Foundayo is driven largely by its oral formulation, which eliminates the need for weekly injections that characterize other GLP-1 medications. Market research consistently shows that needle aversion is the single biggest barrier to GLP-1 medication adoption, and Foundayo's pill form directly addresses this obstacle.
"Foundayo represents a genuine inflection point for the GLP-1 market. The oral formulation dramatically lowers the barrier to entry for patients, and the early prescription data suggests the addressable market is significantly larger than anyone had modeled." - Louise Chen, Senior Pharmaceutical Analyst, Cantor Fitzgerald
Competitive Landscape
Eli Lilly's success with Foundayo puts additional pressure on competitor Novo Nordisk, which has been developing its own oral semaglutide formulation. Novo Nordisk's stock declined 4% on the news as investors recalibrated the competitive dynamics of the weight loss medication market.
The broader GLP-1 market is projected to reach $150 billion in annual sales by 2030, up from approximately $40 billion in 2025. Eli Lilly's early success with the oral formulation positions the company to capture a disproportionate share of this growth, particularly as patent protections and manufacturing capacity become key competitive differentiators.
Supply Chain Considerations
The surge in demand has raised questions about whether Eli Lilly can manufacture enough Foundayo to meet prescriptions. The company has invested heavily in manufacturing capacity, including a $5.3 billion facility in Lebanon, Indiana, that began producing oral formulations in late 2025. However, if demand continues to outpace projections, supply constraints could emerge in the second half of 2026.
Eli Lilly executives addressed this concern during a brief investor call, stating that current manufacturing capacity can support approximately 3 million monthly prescriptions by mid-2026, with additional capacity coming online throughout the year. The company expressed confidence that it can avoid the supply shortages that have plagued competitor products.
Analyst Reactions
Wall Street analysts overwhelmingly raised their price targets for Eli Lilly following the disclosure. The consensus price target rose to $1,050 from $890, with some analysts setting targets as high as $1,200, implying further upside from current levels. The stock is now trading at approximately 55 times forward earnings, a premium valuation that reflects the market's confidence in the company's growth trajectory.
What It Means for Patients
For patients, the strong commercial reception of Foundayo is a positive signal that could lead to improved access over time. High demand typically accelerates insurance coverage decisions and drives investment in manufacturing capacity, both of which benefit patients seeking affordable access to the medication. However, patients are advised to work closely with their healthcare providers rather than relying on availability-driven prescription decisions.
